Additionally, the assessment of immune checkpoint blockade-related gene signatures (PD-1, PD-L1, and CTLA-4)18, whether expressed in tumor or immune cells, does not fully encompass the intricate tumor microenvironment involved in the immunotherapy response. The gene discussed is CTLA4; the disease is neoplasm.